The effect of human myelomonocytic leukemic cell line (M20) derived IL-1 inhibitor on human erythroid cell development.
The effect of an inhibitor of IL-1, purified from a human myelomonocytic cell line (M20) on the development of human erythroid cell development was studied. The inhibitor, is a protein of 52 kD molecular weight that is distinct immunologically and functionally from other reported IL-1 inhibitors. The experiments were performed in a two-phase culture system that allows separation of the erythroid cell development into an erythropoietin (EPO)-independent phase, where early erythroid-committed BFUe proliferate and differentiate into the more mature progenitors, CFUe, and EPO-dependent phase, where CFUe further proliferate and mature into hemoglobin-containing orthochromatic normoblasts. The results indicated that in both developmental stages the M20-derived inhibitor reversibly blocked cell proliferation without interfering with cell differentiation.
Fibach
E
E
Department of Hematology, Hadassah University Hospital, Jerusalem, Israel.
Rigel
M
M
Peled
T
T
Treves
A J
AJ
Barak
V
V
D015672:Erythroid Precursor Cells / Q000166:cytology* / Q000187:drug effects*; D006801:Humans; D007375:Interleukin-1 / Q000037:antagonists & inhibitors*; D015479:Leukemia, Myelomonocytic, Acute / Q000473:pathology*; D009000:Monocytes / Q000737:chemistry / Q000166:cytology; D009363:Neoplasm Proteins / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
D007375:Interleukin-1; D009363:Neoplasm Proteins